Bromocriptine is in a class of medications called dopamine receptor agonists
Mechanism of Action
5, 25, 50 and 100 mg) has been established in six patients with Parkinson's disease
S
D
Carson City, NV – Today, Attorney General Aaron D
Bromocriptine is a sympatholytic D2-dopamine agonist that has been recently approved for the treatment of type 2 diabetes
Bromocriptine mesylate is a dopamine receptor agonist, which activates post-synaptic dopamine receptors
Bromocriptine mesylate (bromocriptine) is a central dopamine receptor agonist approved for the treatment of T2DM in the United States in 2009
It has a role as an antiparkinson drug, a hormone antagonist, a dopamine agonist and an antidyskinesia agent
The dopaminergic neurons in the tuberoinfundibular process modulate the secretion of prolactin from the anterior pituitary by secreting a prolactin inhibitory factor (thought to be dopamine); in the corpus striatum the
Concomitant use with dopamine antagonists, such as neuroleptic agents, may diminish the effectiveness of both drugs and is not recommended
Rather, its effects are mediated via resetting of dopaminergic and Dopamine agonists (DAs), such as bromocriptine (BRC) and cabergoline (CAB) are the first-line drugs for the treatment of patients with idiopathic hyperprolactinemia and prolactinomas ( 3, 7 )
In the dose range studied, bromocriptine appears to be a complete dopamine agonist, although 100 mg was less effective than 50 mg in two patients
dopamine, are inhibited by dopamine antagonists and suggest a direct action of bromocriptine on striatal dopamine receptors
Neuroleptic malignant syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with the rapid withdrawal of dopaminergic medications
Description: Mechanism of Action: Bromocriptine is a dopamine D 2 agonist which activates postsynaptic dopamine receptors in the tuberoinfundibular pathway that inhibits the secretion of prolactin from the anterior pituitary and may lower blood level of growth hormone
Low concentrations of bromocriptine, dopamine have been shown to stimulate prolactin release from cultured pituitary tumor cell line GH4ZR7 cells while high concentrations inhibited the release